Cancer Family
Retroperitoneal Neoplasm
CI-CAN-00000341Explore in graph →
Non-malignant67 active trials1 approved drugs4 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000341Explore in graph →
Clinical trials
299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04860700 | The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma | completed | Phase 2 | 27 | Peking Union Medical College HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT03008369 | Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05174455 | Niraparib for the Treatment of Leiomyosarcoma | withdrawn | Phase 2 | 0 | David Liebner, MDOTHER | 0 | Sep 18, 2023 | clinicaltrials |
| NCT05885399 | The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment | unknown | Phase 2 | 5 | Peking Union Medical College HospitalOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05885386 | A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05883085 | A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL | unknown | Phase 2 | 10 | Peking Union Medical College HospitalOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05858177 | The Efficacy and Safety of Temozolomide in Patients With MPPGL(MPPGL) | completed | Phase 2 | 62 | Peking Union Medical College HospitalOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT04276597 | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.(PUTNET) | withdrawn | Phase 2 | 0 | Excel Diagnostics and Nuclear Oncology CenterOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05302570 | Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS(PROTONS-RPS) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT04320589 | the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma | completed | Phase 2 | 30 | National Cancer Institute, EgyptOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT03923257 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | withdrawn | Phase 1 / Phase 2 | 0 | Sue O'DorisioOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT01967576 | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT02468193 | Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | May 6, 2020 | clinicaltrials |
| NCT01635907 | Dovitinib in Neuroendocrine Tumors | completed | Phase 2 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT01566123 | Trial of Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma (RETRO-WTS) | completed | Phase 1 / Phase 2 | 37 | University Hospital HeidelbergOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00874614 | A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | unknown | Phase 2 | 74 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 20, 2020 | clinicaltrials |
| NCT01833832 | Surgery and Heated Chemotherapy for Adrenocortical Carcinoma | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02720484 | Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer | terminated | Phase 2 | 10 | Northwestern UniversityOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT00453895 | Sunitinib in Refractory Adrenocortical Carcinoma(SIRAC) | completed | Phase 2 | 39 | University of WuerzburgOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT01262235 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | completed | Phase 1 / Phase 2 | 68 | Arbutus Biopharma CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01413503 | A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors | completed | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT02001051 | Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2018 | clinicaltrials |
| NCT00003453 | Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer | terminated | Phase 2 | 6 | Burzynski Research InstituteOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT03257891 | Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines(CabACC) | unknown | Phase 2 | 25 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01340794 | Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma | terminated | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 3 | Sep 21, 2017 | clinicaltrials |
| NCT00028106 | 131MIBG to Treat Malignant Pheochromocytoma | completed | Phase 2 | 32 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT03145285 | Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma(ABACUS) | unknown | Phase 2 | 10 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01514526 | Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma | completed | Phase 2 | 17 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT00458952 | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | completed | Phase 1 / Phase 2 | 24 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02587169 | Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum(GEIS-27) | unknown | Phase 1 / Phase 2 | 40 | Broto, Javier Martín, M.D.INDIV | 1 | Oct 27, 2015 | clinicaltrials |
| NCT01152827 | RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid(PheoCarcRAD001) | completed | Phase 2 | 33 | Seoul National University HospitalOTHER | 1 | May 20, 2015 | clinicaltrials |
| NCT00997594 | Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation | completed | Phase 2 / Phase 3 | 18 | Mie UniversityOTHER | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00469469 | Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma | withdrawn | Phase 2 | 0 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT00831844 | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 2 | 116 | National Cancer Institute (NCI)NIH | 3 | Mar 30, 2015 | clinicaltrials |
| NCT00848016 | Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 7, 2014 | clinicaltrials |
| NCT00778817 | IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2014 | clinicaltrials |
| NCT00002608 | Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors | completed | Phase 2 | 30 | Ottawa Regional Cancer CentreOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01255137 | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Jun 27, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00002921 | S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery | terminated | Phase 2 | 13 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 5, 2012 | clinicaltrials |
| NCT00071058 | Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2012 | clinicaltrials |
| NCT00466856 | Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors | terminated | Phase 2 | 10 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 18, 2012 | clinicaltrials |
| NCT00324012 | Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma | completed | Phase 2 | 19 | Rigshospitalet, DenmarkOTHER | 1 | Feb 22, 2012 | clinicaltrials |
| NCT00454103 | Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy | completed | Phase 1 / Phase 2 | — | University of WuerzburgOTHER | 1 | Aug 18, 2010 | clinicaltrials |
| NCT00786110 | Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients(PAXO) | unknown | Phase 2 | 30 | University of Turin, ItalyOTHER | 1 | Feb 24, 2009 | clinicaltrials |
| NCT00001339 | A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Jun 12, 2024source: clinicaltrials